Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2014 Feb;61(2):380-2. doi: 10.1002/pbc.24756. Epub 2013 Sep 9.

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

Author information

  • 1Nationwide Children's Hospital, Columbus, Ohio.

Abstract

TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.

© 2013 Wiley Periodicals, Inc.

KEYWORDS:

c-Met inhibition; developmental therapeutics; preclinical testing

PMID:
24019233
[PubMed - indexed for MEDLINE]
PMCID:
PMC3961752
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk